$2.88
0.11[3.97%]
Last update: 9:27AM Get Real Time Here
Lumos Pharma
(NASDAQ:LUMO)Lumos Pharma Stock (NASDAQ:LUMO), Analyst Ratings, Price Targets, Predictions
Lumos Pharma Inc has a consensus price target of $15.25, established from looking at the 19 latest analyst ratings. The last 3 analyst ratings were released from HC Wainwright & Co., Oppenheimer, and HC Wainwright & Co. on March 20, 2024, March 8, 2024, and March 8, 2024. With an average price target of $24 between HC Wainwright & Co., Oppenheimer, and HC Wainwright & Co., there's an implied 766.43% upside for Lumos Pharma Inc from these 3 analyst ratings.
Analyst Firms Making Recommendations1
HC Wainwright & Co.
Oppenheimer
Cantor Fitzgerald
Jefferies
1calculated from analyst ratings published within the last 3 years
Analyst Ratings for Lumos Pharma
date | ticker | Buy Now | Company | Current price | Upside/Downside | Analyst Firm | Analyst & % Accurate | Price Target Change | Rating Change | Previous / Current Rating | Get Alert |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 03/20/2024 | LUMO | Buy Now | Lumos Pharma | $2.77 | 910.83% | HC Wainwright & Co. | Edward White | → $28 | Reiterates | Buy → Buy | Get Alert |
| 03/08/2024 | LUMO | Buy Now | Lumos Pharma | $2.77 | 477.62% | Oppenheimer | Leland Gershell | $16 → $16 | Maintains | Outperform | Get Alert |
| 03/08/2024 | LUMO | Buy Now | Lumos Pharma | $2.77 | 910.83% | HC Wainwright & Co. | Edward White | → $28 | Reiterates | Buy → Buy | Get Alert |
| 12/11/2023 | LUMO | Buy Now | Lumos Pharma | $2.77 | 477.62% | Oppenheimer | Leland Gershell | $17 → $16 | Maintains | Outperform | Get Alert |
| 12/07/2023 | LUMO | Buy Now | Lumos Pharma | $2.77 | 910.83% | HC Wainwright & Co. | Edward White | → $28 | Reiterates | Buy → Buy | Get Alert |
| 09/06/2023 | LUMO | Buy Now | Lumos Pharma | $2.77 | 910.83% | HC Wainwright & Co. | Edward White | → $28 | Reiterates | Buy → Buy | Get Alert |
| 08/22/2023 | LUMO | Buy Now | Lumos Pharma | $2.77 | 261.01% | Cantor Fitzgerald | Charles Duncan | → $10 | Reiterates | Overweight → Overweight | Get Alert |
| 08/15/2023 | LUMO | Buy Now | Lumos Pharma | $2.77 | 261.01% | Cantor Fitzgerald | Charles Duncan | $14 → $10 | Maintains | Overweight | Get Alert |
| 08/10/2023 | LUMO | Buy Now | Lumos Pharma | $2.77 | 513.72% | Oppenheimer | Leland Gershell | $18 → $17 | Maintains | Outperform | Get Alert |
| 08/10/2023 | LUMO | Buy Now | Lumos Pharma | $2.77 | 910.83% | HC Wainwright & Co. | Edward White | → $28 | Reiterates | Buy → Buy | Get Alert |
| 07/24/2023 | LUMO | Buy Now | Lumos Pharma | $2.77 | 405.42% | Cantor Fitzgerald | Charles Duncan | → $14 | Reiterates | Overweight → Overweight | Get Alert |
| 06/22/2023 | LUMO | Buy Now | Lumos Pharma | $2.77 | 910.83% | HC Wainwright & Co. | Edward White | → $28 | Reiterates | Buy → Buy | Get Alert |
| 05/04/2023 | LUMO | Buy Now | Lumos Pharma | $2.77 | 910.83% | HC Wainwright & Co. | Edward White | → $28 | Reiterates | → Buy | Get Alert |
| 03/06/2023 | LUMO | Buy Now | Lumos Pharma | $2.77 | 910.83% | HC Wainwright & Co. | Edward White | → $28 | Reiterates | → Buy | Get Alert |
| 12/08/2022 | LUMO | Buy Now | Lumos Pharma | $2.77 | 152.71% | Jefferies | Eun Yang | $17 → $7 | Downgrade | Buy → Hold | Get Alert |
| 11/15/2022 | LUMO | Buy Now | Lumos Pharma | $2.77 | 152.71% | Jefferies | Eun Yang | → $7 | Downgrade | Buy → Hold | Get Alert |
| 07/20/2022 | LUMO | Buy Now | Lumos Pharma | $2.77 | 622.02% | Oppenheimer | Leland Gershell | → $20 | Initiates | → Outperform | Get Alert |
| 11/04/2021 | LUMO | Buy Now | Lumos Pharma | $2.77 | 910.83% | HC Wainwright & Co. | Edward White | — | Maintains | Buy | Get Alert |
| 07/21/2021 | LUMO | Buy Now | Lumos Pharma | $2.77 | 874.73% | HC Wainwright & Co. | Edward White | — | Maintains | Buy | Get Alert |
FAQ
What is the target price for Lumos Pharma (LUMO)?
The latest price target for Lumos Pharma (NASDAQ: LUMO) was reported by HC Wainwright & Co. on March 20, 2024. The analyst firm set a price target for $28.00 expecting LUMO to rise to within 12 months (a possible 872.22% upside). 13 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Lumos Pharma (LUMO)?
The latest analyst rating for Lumos Pharma (NASDAQ: LUMO) was provided by HC Wainwright & Co., and Lumos Pharma reiterated their buy rating.
When was the last upgrade for Lumos Pharma (LUMO)?
There is no last upgrade for Lumos Pharma.
When was the last downgrade for Lumos Pharma (LUMO)?
The last downgrade for Lumos Pharma Inc happened on December 8, 2022 when Jefferies changed their price target from $17 to $7 for Lumos Pharma Inc.
When is the next analyst rating going to be posted or updated for Lumos Pharma (LUMO)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Lumos Pharma, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Lumos Pharma was filed on March 20, 2024 so you should expect the next rating to be made available sometime around March 20, 2025.
Is the Analyst Rating Lumos Pharma (LUMO) correct?
While ratings are subjective and will change, the latest Lumos Pharma (LUMO) rating was a reiterated with a price target of $0.00 to $28.00. The current price Lumos Pharma (LUMO) is trading at is $2.88, which is within the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.